CL2013002631A1 - Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura. - Google Patents
Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura.Info
- Publication number
- CL2013002631A1 CL2013002631A1 CL2013002631A CL2013002631A CL2013002631A1 CL 2013002631 A1 CL2013002631 A1 CL 2013002631A1 CL 2013002631 A CL2013002631 A CL 2013002631A CL 2013002631 A CL2013002631 A CL 2013002631A CL 2013002631 A1 CL2013002631 A1 CL 2013002631A1
- Authority
- CL
- Chile
- Prior art keywords
- protein
- virus
- ipnv
- avirulent
- pancreatic necrosis
- Prior art date
Links
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 title abstract 3
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 4
- 208000009663 Acute Necrotizing Pancreatitis Diseases 0.000 abstract 1
- 206010058096 Pancreatic necrosis Diseases 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 239000002243 precursor Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Un virus de la necrosis pancreática infecciosa (IPNV) avirulento vivo que comprende un ácido nucleico que codifica una proteína VP2 madura o una proteína VP2 precursora, que comprende una secuencia de aminoácidos que tiene al menos un 85% de identidad de secuencia con la SEQ ID NO. 1, donde los residuos de amino ácidos en las posiciones 252, 281, 282 y 319 de la proteína son Asn, Ser, Asp y Glu, respectivamente, donde la proteína causante de¡ virus avirulento no revierte a un virus virulento después de al menos 3 pases en huéspedes que se sabe que son susceptibles a IPNV. Una vacuna que comprende dicho virus y dicho virus para la profilaxis o el tratamiento de la enfermedad necrosis pancreática infecciosa, también son parte de la presente invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO20110402 | 2011-03-16 | ||
| NO20110650A NO332608B2 (no) | 2011-03-16 | 2011-05-02 | Levende avirulent IPNV og vaksine for profylakse eller behandling av IPN-sykdom hos fisk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013002631A1 true CL2013002631A1 (es) | 2014-07-25 |
Family
ID=46207632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013002631A CL2013002631A1 (es) | 2011-03-16 | 2013-09-12 | Virus de la necrosis pancreatica infecciosa (ipnv) avirulento porque comprende proteina vp2 madura. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20140072591A1 (es) |
| EP (1) | EP2686011B8 (es) |
| JP (1) | JP2014513932A (es) |
| AU (1) | AU2012203610A1 (es) |
| CA (1) | CA2830184A1 (es) |
| CL (1) | CL2013002631A1 (es) |
| DK (1) | DK2686011T3 (es) |
| ES (1) | ES2647073T3 (es) |
| NO (2) | NO332608B2 (es) |
| PT (1) | PT2686011T (es) |
| RU (1) | RU2013146020A (es) |
| WO (1) | WO2012078051A2 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400311D0 (en) * | 2014-01-08 | 2014-02-26 | Aqua Gen As | Treating Susceptibility |
| WO2016005796A1 (en) * | 2014-07-11 | 2016-01-14 | Fundacion Fraunhofer Chile Research | Agent with antiviral properties for preventing or treating individuals exposed to a virus of the birnaviridae family |
| GB2533618B (en) * | 2014-12-23 | 2019-11-13 | The Marine Biological Ass Of The United Kingdom | Type B DWV for use in superinfection exclusion protection of Apis mellifera against Type A DWV |
| GB201505310D0 (en) | 2015-03-27 | 2015-05-13 | Fvg Ltd | IPN virus genome mutations and codon interactions |
| BR112018015527A2 (pt) | 2016-02-02 | 2018-12-26 | Benchmark Animal Health Ltd | métodos para produção de vírus |
| WO2023160425A1 (zh) * | 2022-02-24 | 2023-08-31 | 中国水产科学研究院黑龙江水产研究所 | 一种鲑鳟鱼传染性造血器官坏死病和传染性胰脏坏死病单价佐剂疫苗及其二联佐剂疫苗和制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999050419A2 (en) * | 1998-03-31 | 1999-10-07 | University Of Maryland Biotechnology Institute | A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts |
-
2011
- 2011-05-02 NO NO20110650A patent/NO332608B2/no not_active IP Right Cessation
-
2012
- 2012-03-14 CA CA2830184A patent/CA2830184A1/en not_active Abandoned
- 2012-03-14 WO PCT/NO2012/050040 patent/WO2012078051A2/en not_active Ceased
- 2012-03-14 RU RU2013146020/10A patent/RU2013146020A/ru unknown
- 2012-03-14 NO NO12725287A patent/NO2686011T3/no unknown
- 2012-03-14 DK DK12725287.2T patent/DK2686011T3/da active
- 2012-03-14 ES ES12725287.2T patent/ES2647073T3/es active Active
- 2012-03-14 PT PT127252872T patent/PT2686011T/pt unknown
- 2012-03-14 JP JP2013558807A patent/JP2014513932A/ja active Pending
- 2012-03-14 US US14/005,333 patent/US20140072591A1/en not_active Abandoned
- 2012-03-14 AU AU2012203610A patent/AU2012203610A1/en not_active Abandoned
- 2012-03-14 EP EP12725287.2A patent/EP2686011B8/en not_active Not-in-force
-
2013
- 2013-09-12 CL CL2013002631A patent/CL2013002631A1/es unknown
-
2015
- 2015-12-28 US US14/980,182 patent/US20160122728A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012078051A3 (en) | 2012-12-27 |
| PT2686011T (pt) | 2017-11-23 |
| EP2686011B8 (en) | 2017-10-04 |
| JP2014513932A (ja) | 2014-06-19 |
| RU2013146020A (ru) | 2015-04-27 |
| DK2686011T3 (da) | 2017-11-27 |
| EP2686011B1 (en) | 2017-08-30 |
| WO2012078051A2 (en) | 2012-06-14 |
| EP2686011A2 (en) | 2014-01-22 |
| ES2647073T3 (es) | 2017-12-19 |
| AU2012203610A1 (en) | 2013-10-17 |
| US20160122728A1 (en) | 2016-05-05 |
| CA2830184A1 (en) | 2012-06-14 |
| NO2686011T3 (es) | 2018-01-27 |
| NO332608B1 (no) | 2012-11-19 |
| US20140072591A1 (en) | 2014-03-13 |
| NO20110650A1 (no) | 2012-09-17 |
| NZ615974A (en) | 2015-09-25 |
| NO332608B2 (no) | 2012-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017000999A1 (es) | Polipéptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos. | |
| MX2015013065A (es) | Proteinas f de rsv de prefusion y su uso. | |
| WO2015024668A3 (en) | Respiratory syncytial virus (rsv) vaccine | |
| MX2018007860A (es) | Vacunas recombinantes contra el zika. | |
| MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
| CO7160021A2 (es) | Virus del herpes aviar recombinantes multivalentes y vacunas para inmunizar especies aviares | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| EA201491754A1 (ru) | Вакцина против rsv | |
| ES2673556T3 (es) | Vacunas para el VHS-2 | |
| SA515360198B1 (ar) | لقاحات غمس الوحدات الفرعية للسمك | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| MX344103B (es) | Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle. | |
| EA201991041A1 (ru) | Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения | |
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| DK1881845T3 (da) | Nipah-virusvacciner | |
| PH12021553231A1 (en) | Hepatitis b core protein allosteric modulators | |
| PH12014501388A1 (en) | A recombinant koi herpesvirus (khv) and vaccine for the prevention of a disease caused by khv | |
| MX377803B (es) | Proteinas de consenso para el virus de la enfermedad de la fiebre aftosa (fmdv), secuencias de codificacion para estas y vacunas elaboradas a partir de estas. | |
| EA202191145A1 (ru) | Вакцина виб 4/91 с гетерологичным шиповидным белком | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| FI3220937T3 (fi) | Pneumolysiinimutantteja ja menetelmiä niiden käyttämiseksi | |
| MX2015013748A (es) | Capsides estabilizadas de virus de la fiebre aftosa. | |
| PE20190121A1 (es) | Virus atenuados de bronquitis infecciosa | |
| CO2017001614A2 (es) | Vacuna en vector recombinante de adenovirus aviar serotipo 9 | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina |